SOVREMENNYE PODKhODY K MOLEKULYaRNOY I PERSONALIZIROVANNOY TERAPII BOLEZNI PARKINSONA


Cite item

Full Text

Abstract

About the authors

S N Illarioshkin

Научный центр неврологии

Москва

References

  1. Ганькина, о.А. особенности течения болезни Паркинсона при гетерозиготном носительстве мутаций в гене глюкоцереб- розидазы А. / о.А. Ганькина, е.е. Васенина, о.С. Левин, е.Ю. Федотова, С.Н. Иллариошкин // Журн. неврологии и психиатрии им. С.С. Корсакова. - 2016. - № 6. - С. 71-76.
  2. Иллариошкин, С.Н. Этапы прогрессирования болезни Паркинсона. Что определяет выживаемость и прогноз? / С.Н. Илла- риошкин // Вестн. РоссийскойВоенно-мед. акад. - 2013. - № 4 (Прилож. 2). - С. 11-13.
  3. Akram, H. l-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson’s disease / H. Akram, C. Wu, J. Hyam, et al. // Mov. Disord.- 2017. - V. 32. - P. 874-883.
  4. Alcalay, R.N. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study / R.N. Alcalay, E. Caccappolo, H. Mejia-Santana, et al. // Neurology. -2012. -V. 78. - P.1434-1440.
  5. Bhattacharjee, S. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson’s disease patients / S. Bhattacharjee, J.G. Talbot, P. Vijayashankar // Parkinsonism Relat.Disord. - 2017. - V.34. - P.69-70.
  6. Braczynski, A.K. Vaccination strategies in tauopathies and synucleinopathies / A.K. Braczynski, J.B. Schulz, J.P. Bach // J. Neurochem. - 2017. - V. 143. - P.467-488.
  7. Brundin, P. Therapeutic approaches to target alpha-synuclein pathology / P. Brundin, K.D. Dave, J.Y. Kordower// Experim. Neurol. -2017. - V. 298. - P. 225-235.
  8. Bu, L.-L. Toward precision medicine in Parkinson disease / L.-L Bu., K.Yang, W.-X. Xiong, et al. // Ann. Transl. Med. - 2016. - V. 4(2). - Art. 26.
  9. Collins, F.S. A new initiative on precision medicine / F.S. Collins, H. Varmus // N. Engl. J. Med. - 2015. - V.372. - P. 793-795.
  10. Dzoljic, E. Pharmacogenetics of drug response in Parkinson’s disease / E.Dzoljic, I. Novakovic, M. Krajinovic, et al. // Int. J.Neurosci. -2015. - V. 125.-P. 635-644.
  11. Ghiglieri, V. Alpha-synuclein: From early synaptic dysfunction to neurodegeneration / V. Ghiglieri, V. Calabrese, P. Calabresi// Front. Neurol. - 2018. - V. 9. - Art. 295.
  12. Jameson, J.L. Precision medicine - personalized, problematic, and promising / J.L. Jameson, D.L. Longo // N. Engl. J. Med. - 2015. - V. 372. - P. 2229-2234.
  13. Lee, S.H. Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases / S.H. Lee, H. Cho, J.Y. Choi, et al. // Mov. Disord. -2018.- V. 33.- P. 262-272.
  14. Masellis, M. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study / M. Masellis, S. Collinson, N. Freeman, et al. // Brain. - 2016. - V. 139. - P. 2050-2062.
  15. McGuire Kuhl, M. Foxfeed blog: vaccine for Parkinson’s reports positive results from boost study / M. McGuire. Kuhl // MichaelJFox. org https://www.michaeljfox.org/foundation/news-detail.php?vaccine-for-parkinson reports-positive-results-from-boost-study&et_ cid=663719&et_rid (2016).
  16. Meissner, W. Specific active immunotherapy (SAIT) against alpha-synuclein with AFFITOPE® PD01A and PD03A: Results from the AFF009 phase I trial / W. Meissner, A. Pavy-Le Traon, A. Foubert-Samier, et al. // Mov. Disord.- 2018.- V. 33 (Suppl. 2).- S3.
  17. Mittal, S. β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease / S. Mittal, K. Bjørnevik, D.S. Im, et al. // Science. -2017.- V. 357.- P. 891-898.
  18. Mohler, J. Precision medicine: A wider definition / J. Mohler, B. Naja, M. Fain, et al. // J. Am. Geriatr. Soc. - 2015. - V. 63. - P. 1971-1972.
  19. Olanow, C.W. Gene therapy for Parkinson disease-a hope, or a dream? / C.W. Olanow// Nat. Rev. Neurol. -2014. - V. 10. - P. 186-187.
  20. Pagan, F. Nilotinib increases dopamine metabolism and reduces oligomeric/total alpha-synuclein ratio in Parkinson’s disease / F. Pagan, M. Hebron, Y. Torres-Yaghi, et al. // 2018 International Congress of Parkinson’s Disease and Movement Disorders. - Hong Kong. - October 5-9, 2018. - Late-Breaking Abstracts. - LBA01.
  21. Parnetti, L. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in Parkinson’s disease patients / L. Parnetti, S.Paciotti, P.Eusebi, et al. // Mov. Disord.-2017.- V. 32.- P. 1423-1431.
  22. Peterschmitt, M.J. Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson’s disease patients with a GBA mutation / M.J. Peterschmitt, T. Gasser, S. Isaacson, et al. // 2018 International Congress of Parkinson’s Disease and Movement Disorders. - Hong Kong. - October 5-9, 2018. - Late-Breaking Abstracts. - LBA21.
  23. Poewe, W.Parkinson disease / W. Poewe, K. Seppi, C.M. Tanner, et al. // Nature Rew. - 2017. - V. 3. - Art. 1703.
  24. Schenk, D.B. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers / D.B. Schenk, M. Koller, D.K. Ness, et al. // Mov. Disord. - 2017. - V. 32. - P. 211-218.
  25. Tran, H.T.α-Synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration / H.T. Tran, C.H. Chung, M.Iba, et al. // Cell Rep. -2014. -V. 7. -P. 2054-2065.
  26. West, A.B. Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease / A.B. West // Experiment. Neurol. - 2017. - V. 298. - P. 236-245.

Copyright (c) 2018 Illarioshkin S.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies